Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Telik Inc. (TELK)

1.35 0.00(0.00%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Telik Inc.
2100 Geng Road
Suite 102
Palo Alto, CA 94303
United States - Map
Phone: 650-845-7700
Fax: 650-845-7800

Index Membership:N/A
Industry:Drugs - Generic
Full Time Employees:11

Business Summary 

Telik, Inc., a clinical-stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer. The company’s product candidates are discovered using its proprietary technology, target-related affinity profiling (TRAP), which enables the discovery of small molecule product candidates. Its lead drug product candidate in clinical development includes TELINTRA, a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1, which is under Phase II clinical trial for the treatment of blood disorders associated with low blood cell levels, such as anemia, neutropenia, or thrombocytopenia. The company’s preclinical drug product developments include TLK60404, a small molecule compound, which inhibits Aurora kinase and VEGFR kinase; TLK60357, a small molecule inhibitor of cell division that inhibits the formation of microtubules necessary for cancer cell growth leading to persistent cancer cell cycle block and subsequent cell death at the G2/M phase; and TLK60596, a VEGFR1 and VEGFR2 kinase inhibitor that blocks the formation of new blood vessels in tumors. Telik, Inc. was founded in 1988 and is based in Palo Alto, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Telik Inc.

Key Executives 
Dr. Michael M. Wick M.D., Ph.D., 68
Chairman, Chief Exec. Officer and Pres
Ms. Wendy K. Wee , 61
Principal Financial & Accounting Officer, VP of Fin. and Controller
Mr. William P. Kaplan Esq., 60
VP of Legal Affairs, Gen. Counsel and Sec.
Dr. Gail L. Brown M.D., 63
Chief Medical Officer and Sr. VP
Dr. Steven R. Schow Ph.D., 64
VP of Research
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders